GHK-Cu mechanism, half-life, primary literature, topical and systemic angles. Research-grade reference for serious operators.
A naturally occurring tripeptide with high copper-binding affinity, sold for research use only and most often referenced in the skin, hair, and tissue-remodeling literature.
GHK-Cu stands for glycyl-L-histidyl-L-lysine, copper-bound. The peptide portion — GHK — is a three-amino-acid sequence found naturally in human plasma. The copper-bound complex, GHK-Cu, is the active form most of the literature describes. The tripeptide chelates copper(II) ions with high affinity, and the resulting complex is what the cosmetic and dermatologic corpus has been studying for forty years.
The biology of GHK and GHK-Cu was characterized by Loren Pickart beginning in the 1970s. Pickart's collaborators have published the bulk of the foundational work on this molecule across half a century. If you read one author on GHK-Cu, you read Pickart. His 2018 review with Margolina in the International Journal of Molecular Sciences — "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data" — is the gene-expression-era summary of the corpus and the right entry point for a serious reader.
In commercial markets GHK-Cu is sold two ways. As a topical cosmetic ingredient it appears in serums, creams, and scalp formulations across the legal cosmetic supply chain. As an injectable it is sold RUO — research use only — by peptide vendors. The two product categories have different regulatory postures and different evidence bases. This page covers both.
It is the math operators are choosing to do under their own labs, with their own physician relationships, eyes open.
This page is mechanism, half-life, and where the literature lives — not bro-science.
GHK is a copper chaperone — a small molecule that delivers a metal ion, in this case copper(II), to specific cellular destinations. Copper is a cofactor for a long list of enzymes involved in extracellular matrix remodeling, antioxidant defense, and angiogenesis. Delivering copper to the right cellular compartment, in a controlled form, is the molecular root of GHK-Cu's activity.
The published work documents several converging effects:
Extracellular matrix modulation. GHK-Cu upregulates expression of collagen, elastin, and decorin in fibroblast culture and in human skin biopsies in published topical studies. Lysyl oxidase, the copper-dependent enzyme that crosslinks collagen, is part of this pathway.
Antioxidant and anti-inflammatory gene expression. Pickart's later work, leveraging Broad Institute Connectivity Map data, documents large-scale gene-expression changes consistent with stress-response and tissue-protective programs.
Wound repair and angiogenesis. Animal models and human topical studies document accelerated wound closure and improved tissue quality in chronic wound contexts. This is the cleanest tier of the corpus.
Hair follicle effects. Topical GHK-Cu in scalp formulations has been studied in androgenetic alopecia contexts. The corpus is smaller and noisier than the skin corpus.
The honest summary: GHK-Cu is one of the most-studied peptides on this site for its intended cosmetic application. The topical evidence base is real. The systemic-injection evidence base, particularly for the recovery and longevity contexts the founder-biohacker community uses it in, is far thinner.
GHK-Cu plasma half-life is short — minutes — in the literature. The peptide is small, it is rapidly cleared, and its biology appears to operate at tissue residence times longer than plasma residence times because the delivered copper persists at the target.
Topical is the dominant route in the cosmetic and dermatologic literature. Most of the published human evidence on GHK-Cu — the part of the corpus that touches Tier 1 territory — is topical. Penetration enhancement varies by formulation.
Subcutaneous injection is the dominant route in research contexts where systemic effects are studied. Animal models and the small body of human-injected work both use subcutaneous routes.
Oral GHK is poorly characterized. The peptide is degraded by digestive enzymes and oral preparations are not well-supported by the literature.
Frequency of administration varies. Topical applications are commonly daily or twice-daily. Injected research protocols vary widely.
Read this section twice.
Tier 1 — Randomized controlled trials in humans. A small but real corpus on topical GHK-Cu in dermatologic and cosmetic indications. Studies on photoaged skin, periorbital wrinkles, and chronic wound healing exist in peer-reviewed journals. Sample sizes are small to moderate. This is the highest-tier evidence on this page across all three Wolverine-stack compounds.
Tier 2 — Open-label and single-arm human work. Multiple studies on topical formulations across skin and hair indications. Smaller corpus on injected GHK-Cu in non-cosmetic contexts.
Tier 3 — Animal and mechanistic. Large. Pickart's lab and independent groups across five decades — wound healing models, cell culture models, gene expression profiling. Pickart and Margolina, 2018 (International Journal of Molecular Sciences) is the synthesis paper.
Tier 4 — Operator n=1. Substantial. Topical use reports cluster around skin texture and tone. Injected use reports cluster around recovery contexts and frequently appear stacked with BPC-157 and TB-500.
The literature is the strongest of the three Wolverine-stack compounds for its topical cosmetic application. The literature is mostly preclinical for the systemic-injection use case the founder-biohacker community talks about most. The marketing does not always make that distinction. This page does.
Topical reports. Skin texture and tone changes commonly reported within four to eight weeks of consistent topical use. Periorbital and forehead reports are most common. Hair density anecdotes from scalp-applied formulations are noisier — some operators report meaningful changes, others report nothing.
Injection reports. Most often paired with BPC-157 and TB-500 in recovery stacks. Some operators describe blue-green discoloration at the injection site, which is the copper signature and is cosmetic, not systemic. Reported subjective effects on connective tissue build slowly.
Stack patterns. GHK-Cu is the third leg of the Wolverine stack alongside BPC-157 and TB-500. It is also one of the cornerstone compounds in what the community calls the GLOW stack — a skin-and-hair-focused protocol that pairs GHK-Cu (often topical) with epithalon and occasionally other anti-aging compounds.
This is community framing summarized neutrally. It is not endorsement.
Systemic effects of injected GHK-Cu in humans. Under-characterized. Most of the human evidence base is topical. The injected use case the operator community runs is not well-supported by indexed human trials.
Copper accumulation risk at sustained injected exposure. Not well-studied. Copper is a regulated micronutrient and chronic excess exposure has known risks. What chronic injected GHK-Cu use looks like at the copper-balance level in a 40-year-old founder is a real open question.
Dose-response outside topical applications. Unclear. Community injected dosing varies by an order of magnitude. The literature does not arbitrate.
Hair follicle outcomes. The androgenetic alopecia literature on topical GHK-Cu is smaller and noisier than the skin literature. The signal is real but uneven.
Vendor variation. Copper loading varies across vendors. The peptide may ship as a 1:1 GHK:Cu complex or in formulations with different copper stoichiometry. COAs matter here more than they do for non-metal-bound peptides.
GHK-Cu is the third leg of the Wolverine stack alongside BPC-157 and TB-500, and it is the cornerstone of the skin-and-hair stack on the cosmetic side. The full peptide map sits in Issue 1: The 2026 Peptide Stack Map — fourteen compounds, mechanism through literature, one page each. Issue 5 goes deeper on the recovery stack; the skin and hair angle gets its own treatment in subsequent issues.
If skin, hair, or aging-of-the-face is why you are reading this page, the lead magnet to pull is the Skin and Hair Peptide Stack PDF — GHK-Cu plus the adjacent compounds operators run alongside it, mechanism through literature, in one document, free.
Adjacent compounds on this site: BPC-157 and TB-500.
The cosmetic-and-systemic peptides serious operators are running. Mechanism, half-life, primary literature, and where the corpus thins. One reference document.
Subscribe to The Compound at https://www.thecompoundbrief.com/subscribe and the PDF lands in your inbox.
For research use only. Not medical advice. Nothing on this page is a recommendation to administer, prescribe, or self-administer any compound.
Disclosure: The operator who publishes The Compound also owns heroxbio.com, an RUO peptide vendor. Full disclosure on the About page.
Topical vs. systemic. What the literature actually shows.
Download the PDF →